Cite this dataset: Couey, V.W. (2026). 85 Prescription Drug Pricing Statistics 2026. RxGrab. CC BY 4.0. https://rxgrab.com/prescription-drug-statistics-2026/
A curated, hyperlink-sourced reference for US prescription drug pricing in 2026. Every stat links to its primary source. We omit any number we cannot verify.
Medical disclaimer: This page is a pricing reference, not medical advice. Drug substitution, dosing, and adherence decisions belong to a licensed clinician or pharmacist. Some patients have legitimate clinical reasons to remain on brand formulations.
US prescription drug net spending crossed $480 billion in 2024 per IQVIA Use of Medicines in the US 2024, against gross spending above $720 billion. The net-vs-gross gap is the rebate stack negotiated between manufacturers and PBMs.
Generics: Volume vs Spend
Share of prescriptions90%
Share of drug spending13.1%
Generics and biosimilars fill 90% of US prescriptions yet account for only 13.1% of prescription drug spending (AAM 2024).
Specialty: Spend vs Volume
Share of drug spending~55%
Share of prescriptions~2%
The mirror image: specialty drugs are ~2% of prescriptions but ~55% of spending (IQVIA 2024).
Cash-Price Floors
$5.32 metformin 500mg (Cost Plus)$4 Walmart genericsCostco: no published listCost Plus: cost + 15% + $5$3 trillion+ generic savings, decade to 2023
What competitive generics do to cash prices once the patent cliff clears.
US brand-name drugs run 4.22x the OECD average and US drugs overall 2.78x, while US generics sit at 67% of the OECD generic price (2022 prices). The multiple lives almost entirely in brands.
Roughly 30% of US adults report not filling a prescription, skipping doses, or cutting pills in half because of cost.Source: KFF Health Tracking Poll on Drug Costs 2023
US Drug Spending
$487 billion#1 US net prescription drug spending in 2024 (after rebates), per IQVIA.
$5.32#18 listed price for 30 tablets of metformin 500mg at Mark Cuban Cost Plus Drugs, including its $5 dispensing fee and before shipping, as of October 2026.
5 of 50#23 brand drugs in the RxGrab 2026 audit had no full generic on the US market: Ozempic, Wegovy, Jardiance, Eliquis (generics FDA-approved December 2019 but not launched) and Xarelto (generic approved only for the 2.5 mg tablet, March 2025).
$55 billion+#24 combined 2024 US sales of the five blockbusters without a full US generic in the RxGrab cohort.
Source: company 10-K disclosures (Novo Nordisk, BMS, Pfizer, Boehringer Ingelheim, Janssen) compiled in RxGrab 2026 auditSource not re-confirmed in our October 2026 review.
2031-2033#25 estimated first generic launch window for semaglutide (Ozempic and Wegovy active ingredient).
15#30 drugs whose Medicare negotiated prices CMS announced on November 25, 2025 in the second IRA cycle, effective January 1, 2027, including Ozempic, Wegovy and Rybelsus.
BX#44 rating denotes "data are insufficient to determine therapeutic equivalence" and is the most common reason a state pharmacy board blocks substitution.
72%#53 of the facilities making active pharmaceutical ingredients (APIs) for the US market were outside the United States as of August 2019 (13% in China), per FDA.
3#56 root causes of drug shortages identified by FDA: too little incentive to make less profitable drugs, a market that does not reward mature quality systems, and logistical and regulatory barriers to recovering from a disruption.
6.4%#67 of Medicare Advantage prior authorization requests were fully or partially denied in 2023; 11.7% of denials were appealed, and 81.7% of appeals overturned the denial.
2027#69 the year (from January 1) CMS final rule CMS-0057-F requires Medicare Advantage and other impacted payers to run prior authorization APIs; its 72-hour and 7-day decision deadlines began January 1, 2026. Prior authorizations for drugs are excluded.
$5#76 monthly Amazon Pharmacy RxPass fee for all eligible generics (more than 50), Prime required; not available to Medicaid or CHIP enrollees or for delivery to California and Washington, as of October 2026.
19#77 drugs on the $4 (30-day) / $10 (90-day) tier of Walmart's Prescription Program list effective March 24, 2025; most other listed generics are $9 / $24.
2003#83 the year the Medicare Modernization Act prohibited Medicare from directly negotiating drug prices, a constraint partially reversed by the 2022 Inflation Reduction Act for selected drugs.
2026#85 the year RxGrab will refresh this dataset; the brand-to-generic pricing landscape changes meaningfully in 12-month windows around major patent cliffs.